Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/aor.14946 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ECLS-SHOCK and DanGer Shock: Implications for optimal temporary mechanical circulatory support use for cardiogenic shock due to acute myocardial infarction.
Can J Cardiol
January 2025
University of Montreal Hospital Center (CHUM) Cardiovascular Center & Research Center (CRCHUM), University of Montreal, Montreal, Quebec, Canada. Electronic address:
Despite concerted efforts to rapidly identify patients with cardiogenic shock complicating acute myocardial infarction (AMI-CS) and provide timely revascularization, early mortality remains stubbornly high. While artificially augmenting systemic flow through the use of temporary mechanical circulatory support (tMCS) devices would be expected to reduce the rate of progression to multi-organ dysfunction and thereby enhance survival, reliable evidence for benefit has remained elusive with lingering questions regarding the appropriate selection of both patients and devices, as well as the timing of device implantation relative to other critical interventions. Further complicating matters are the resource-intensive multidisciplinary systems of care that must be brought to bear in this complex patient population.
View Article and Find Full Text PDFFrontal Fibrosing Alopecia (FFA) Part I - Diagnosis and Clinical Presentation.
J Am Acad Dermatol
January 2025
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL.
Frontal Fibrosing Alopecia (FFA) is a primary lymphocytic cicatricial alopecia predominantly affecting postmenopausal Caucasian women. It is characterized by a progressive frontotemporal hairline recession that presents as a scarring hairless band and is often accompanied by eyebrow and body hair loss. Although initially described in postmenopausal women, FFA has been observed in a broader demographic, including premenopausal women and occasionally men.
View Article and Find Full Text PDFUtilizing artificial intelligence and cellular population data for timely identification of bacteremia in hospitalized patients.
Int J Med Inform
January 2025
Department of Emergency Medicine, China Medical University Hospital, Taichung, Taiwan; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan. Electronic address:
Background: Bacteremia is a critical condition with high mortality that requires prompt detection to prevent progression to life-threatening sepsis. Traditional diagnostic approaches, such as blood cultures, are time-consuming. This limitation has encouraged the exploration of rapid prediction methodologies.
View Article and Find Full Text PDFamVAE: Age-aware multimorbidity clustering using variational autoencoders.
Comput Biol Med
January 2025
Applied Artificial Intelligence Institute, Deakin University, Geelong, Australia.
Multimorbidity, the co-occurrence of multiple chronic conditions within the same individual, is increasing globally. This is a challenge for the single patients, as these individuals are subject to a heavy disease and treatment burden, yet evidence on the epidemiology and consequences of multimorbidity remains underexplored. Historically, studies aiming to understand multimorbidity patterns predominantly utilized cross-sectional data, neglecting the essential temporal dynamics which shape multimorbidity progression.
View Article and Find Full Text PDFArtificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial.
JCO Precis Oncol
January 2025
Translational Research Support Office, National Cancer Center Hospital East, Chiba, Japan.
Purpose: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown promise in treating -amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores the potential of artificial intelligence (AI) in predicting treatment responses to trastuzumab plus pertuzumab (TP) in patients with -amplified mCRC from the phase II TRIUMPH trial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!